Skip to main content

Recent articles

ALX has a Chinese challenger

HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.

Ideaya socks it to GSK

Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.

Where next for TIGIT?

The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.

Roche reins in the TIGIT expectations

Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.

Apollomics shifts to a smaller niche

The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

Gilead’s multiple bets on fast Car production

A three-way race is on to determine which Car-T therapy Gilead will take into pivotal trials.